STOCK TITAN

RenovoRx (RNXT) Stock Price, News & Analysis

RNXT NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
66 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
-23% close of November 14, 2025
1-year change
+6.7% closing prices, November 13, 2025 to November 13, 2026
1-month change
-9.6% closing prices, October 13, 2026 to November 13, 2026

Company Description

RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath®, a U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device. The company’s work centers on high unmet medical needs in cancer, using its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform to deliver therapeutic agents near the tumor site while potentially reducing the toxicities associated with systemic intravenous chemotherapy.

Core business and therapy platform

RenovoRx’s business combines elements of pharmaceutical preparation manufacturing and medical device commercialization. According to the company’s descriptions in multiple press releases, its patented TAMP therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. This approach is intended to limit systemic exposure and may help minimize side effects compared with standard systemic intravenous therapy.

The TAMP platform is enabled by RenovoCath, an FDA-cleared, local drug-delivery device. Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. It is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoCath® device and stand-alone commercialization

RenovoRx is actively commercializing RenovoCath as a stand-alone targeted drug-delivery device. Company disclosures state that RenovoRx has received commercial purchase orders for RenovoCath and is expanding the number of medical institutions initiating orders, including National Cancer Institute-designated centers and community hospitals. Adoption of RenovoCath is described as growing among both new and returning customers, reflecting clinical interest in localized, targeted treatment enabled by the TAMP platform.

The company reports that RenovoCath is used in patient procedures at multiple cancer centers and that repeat purchase orders have been placed by several institutions. RenovoRx has also discussed building a commercial organization, including sales and market development roles, to support broader use of RenovoCath across a domestic network of academic institutions, NCI-designated cancer centers, and high-volume community hospitals.

Drug–device combination candidate (IAG) and TIGeR‑PaC trial

In addition to its cleared device, RenovoRx is evaluating a novel drug–device combination oncology product candidate: intra-arterial gemcitabine delivered via RenovoCath, referred to as IAG. This combination product uses the TAMP therapy platform and is being studied in the ongoing Phase III TIGeR‑PaC clinical trial for patients with locally advanced pancreatic cancer (LAPC). Company communications describe TIGeR‑PaC as a randomized, multi-center trial designed to evaluate intra-arterial administration of gemcitabine using RenovoCath.

IAG is being evaluated by the Center for Drug Evaluation and Research under a U.S. investigational new drug application regulated by the FDA’s 21 CFR 312 pathway. RenovoRx notes that this combination product candidate is currently under investigation and has not been approved for commercial sale. The company also discloses that RenovoCath with gemcitabine has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which would provide seven years of market exclusivity upon new drug application approval by the FDA.

Clinical evidence and scientific rationale

RenovoRx highlights pharmacokinetic (PK) and pharmacodynamic data from a sub‑study of the TIGeR‑PaC trial comparing intra-arterial gemcitabine delivered via TAMP and RenovoCath (IAG) with standard intravenous gemcitabine. According to an abstract presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), TAMP and IAG resulted in reduced systemic levels of gemcitabine and increased levels of its inactive metabolite compared with intravenous administration. A direct correlation was observed between increased metabolite levels and reduced CA 19‑9, a biomarker commonly used to assess potential chemotherapy response.

The company states that by decreasing systemic levels of gemcitabine through limited systemic exposure and rapid conversion to an inactive metabolite, this delivery approach may both increase local drug potency and reduce negative side effects common in pancreatic cancer treatment. These findings are presented by RenovoRx as supportive evidence for the scientific basis of the TAMP platform’s localized approach to targeted chemotherapeutic delivery.

Post‑marketing registry and investigator‑initiated studies

Beyond the TIGeR‑PaC trial, RenovoRx has initiated a post‑marketing observational registry study designed to collect real‑world data on the safety and survival outcomes of patients with solid tumors treated using RenovoCath. Company updates describe this registry as generating real‑world evidence on the use of RenovoCath across solid tumors, with procedures initiated at multiple cancer centers.

RenovoRx also reports supporting capital‑efficient, investigator‑initiated trials in borderline resectable and oligometastatic or metastatic pancreatic cancer. These studies are intended to provide additional data that may further expand the potential clinical utility of the TAMP therapy platform and RenovoCath-enabled treatments.

Commercial and capital strategy

RenovoRx’s disclosures indicate that the company is in the early stages of commercializing its TAMP technology and RenovoCath as a stand‑alone device and has begun generating revenue from device sales. The company has discussed expanding its customer base, fulfilling repeat orders, and exploring additional revenue‑generating activity, either independently or in collaboration with a medical device commercial partner.

From a capital markets perspective, RenovoRx has filed shelf registration statements on Form S‑3 and, according to an 8‑K filed in November 2025, entered into a Capital on Demand™ Sales Agreement with a sales agent. This agreement allows the company to issue and sell shares of common stock from time to time in at‑the‑market offerings or negotiated transactions, providing a mechanism for potential future financing subject to market conditions and company decisions.

Scientific and advisory expertise

The company has announced the expansion of its Scientific Advisory Board (SAB) with recognized experts in pancreatic cancer and interventional oncology. These include a UCLA pancreatic disease surgeon and an interventional oncologist from Gustave Roussy Cancer Centre and University Paris‑Saclay. RenovoRx states that these advisors contribute expertise in surgical oncology, translational oncology research, locoregional cancer therapies, intra‑arterial chemotherapy, and targeted drug delivery, which the company views as directly relevant to the continued development of its TAMP platform and RenovoCath-enabled therapies.

Mission and therapeutic focus

Across its public communications, RenovoRx describes its mission as transforming the lives of cancer patients by providing approaches that enable targeted delivery of diagnostic and therapeutic agents. Its work is concentrated on high unmet medical needs, particularly in pancreatic cancer and other solid tumors where localized, arterial drug delivery may offer a different risk–benefit profile compared with conventional systemic chemotherapy.

Stock Performance

$1.04
-10.34%
-0.12
Last updated: November 13, 2026 at 16:00
+6.7%
Performance 1 year
$50.2M

RenovoRx (RNXT) closed at $1.04 on November 13, 2026. Over the past 12 months, the price has gained 6.7%.

See what a $1,000 investment in RNXT would be worth today

Average down calculator for RNXT

RNXT Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

RenovoRx has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings date, earnings. View all RNXT news →

Financial Highlights

RenovoRx generated $1.1M in revenue in FY2025, retaining a 70.9% gross margin, operating income reached -$12.5M, and net income was -$11.2M. Diluted earnings per share stood at -$0.32. The company generated -$11.0M in operating cash flow. The current ratio was 4.02, measuring current assets divided by current liabilities.

$1.1M
Revenue (FY2025)
-$11.2M
Net Income (FY2025)
-$11.0M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Clinical

TIGeR-PaC final data expected

Final Phase III TIGeR-PaC trial data anticipated sometime in 2027
YEAR
2027
2027 Clinical

Pivotal trial final data

TIGeR-PaC Phase III final data reporting expected sometime in 2027
YEAR
2027
2027 Clinical

TIGeR-PaC topline results

Topline results for pivotal Phase III TIGeR-PaC trial targeted during 2027
YEAR
2027
2027 Clinical

TIGeR-PaC final data readout

Anticipated release of Phase III TIGeR-PaC final data
YEAR
2027
2027 Clinical

Final trial data readout

Final TIGeR-PaC Phase III data expected in 2027; trial requires 86 events for final analysis
YEAR
2027
2027 Clinical

TIGeR-PaC full data readout

Anticipated primary endpoint data for the TIGeR-PaC pivotal trial.
H1
2027
H1 2027 Clinical

TIGeR-PaC Completion

Phase III TIGeR-PaC trial expected to complete patient follow-up and primary endpoint assessment between Jan 1 and Jun 30, 2027.
H1
2027
H1 2027 Clinical

TIGeR‑PaC completion

Expected Phase III TIGeR‑PaC trial completion window (1H 2027) for intra‑arterial gemcitabine program; key clinical milestone.
H1
2027
H1 2027 Clinical

TIGeR-PaC trial completion

Expected completion of TIGeR-PaC Phase III trial in H1 2027 after 86 events; primary endpoint is overall survival.
MAY
01
May 1, 2027 - December 31, 2027 Clinical

TIGeR-PaC final data anticipated

Phase III TIGeR-PaC final data anticipated mid to late 2027; potential pivotal results subject to follow-up and analysis.
MAY
01
May 1, 2027 - December 31, 2027 Clinical

TIGeR-PaC Final Data

Phase III TIGeR-PaC final data expected mid-to-late 2027 for intra-arterial gemcitabine via RenovoCath; enrollment near term.
MAY
01
May 1, 2027 - December 31, 2027 Clinical

Final data readout window

TIGeR-PaC Phase III final data expected mid–late 2027; pivotal readout for intra-arterial oxaliplatin in pancreatic cancer.
MAY
01
May 1, 2027 - December 31, 2027 Clinical

TIGeR-PaC final readout

Phase III TIGeR-PaC final data readout for IAG in locally advanced pancreatic cancer; expected May–Dec 2027.
MAY
01
May 1, 2027 - December 31, 2027 Clinical

TIGeR-PaC final data release

Phase III TIGeR-PaC final data expected mid to late 2027; results could drive regulatory decisions and valuation.
H2
2027
H2 2027 Clinical

TIGeR-PaC initial data

Phase III TIGeR-PaC initial data expected in H2 2027; topline results Jul–Dec 2027; could impact commercial outlook.
H2
2027
H2 2027 Clinical

TIGeR-PaC Topline Data

Topline efficacy and safety results from the Phase III TIGeR-PaC trial expected to be reported between Jul 1 and Dec 31, 2027.
H2
2027
H2 2027 Clinical

Topline data release

Initial topline data from TIGeR-PaC Phase III anticipated in H2 2027 comparing IAG via RenovoCath vs IV gemcitabine+Abraxane.

RenovoRx has 17 upcoming scheduled events. The next event, "TIGeR-PaC final data expected", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the RNXT stock price.

Short Interest History

Last 12 Months

Short interest in RenovoRx (RNXT) currently stands at 998.0 thousand shares, up 15.4% from the previous reporting period, representing 2.3% of the float. Since November 2025, short interest has increased by 47.6%.

Days to Cover History

Last 12 Months

Days to cover for RenovoRx (RNXT) currently stands at 3.5 days, up 114% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 134%. Across the settlements charted above, it has ranged from 1.0 to 3.5 days.

RNXT Company Profile & Sector Positioning

RenovoRx (RNXT) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing RNXT often look at related companies in the same sector, including Rein Therapeutics, Inc. (RNTX), Pliant Therapeutics, Inc. (PLRX), Oncolytics Biotech, Inc. (ONCY), Verrica Pharmaceuticals Inc. (VRCA), and MiNK Therapeutics, Inc. (INKT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RNXT's relative position within its industry.

Frequently Asked Questions

The current stock price of RenovoRx (RNXT) is $1.04 as of November 13, 2026.

The market cap of RenovoRx (RNXT) is approximately $50.2M. Learn more about what market capitalization means .

The FY2025 revenue of RenovoRx (RNXT) is $1.1M, from its most recent completed fiscal year.

The FY2025 net income of RenovoRx (RNXT) is -$11.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of RenovoRx (RNXT) is -$0.32 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of RenovoRx (RNXT) is -$11.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of RenovoRx (RNXT) is 70.9% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of RenovoRx (RNXT), current assets divided by current liabilities, was 4.02 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of RenovoRx (RNXT) is $796K for FY2025, its most recent completed fiscal year.

The operating income of RenovoRx (RNXT) is -$12.5M for FY2025, its most recent completed fiscal year. Learn about operating income.